IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0466161
(2012-05-08)
|
등록번호 |
US-8563311
(2013-10-22)
|
발명자
/ 주소 |
- Amit, Michal
- Itskovitz-Eldor, Joseph
|
출원인 / 주소 |
- Technion Research & Development Foundation Limited
|
인용정보 |
피인용 횟수 :
7 인용 특허 :
5 |
초록
▼
The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno con
The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.
대표청구항
▼
1. A method of propagating mammalian pluripotent stem cells in an undifferentiated, pluripotent and proliferative state under culturing conditions devoid of feeder cells, the method comprising culturing the mammalian pluripotent stem cells in a tissue culture medium which comprises transforming grow
1. A method of propagating mammalian pluripotent stem cells in an undifferentiated, pluripotent and proliferative state under culturing conditions devoid of feeder cells, the method comprising culturing the mammalian pluripotent stem cells in a tissue culture medium which comprises transforming growth factor β1 (TGFβ1) and basic fibroblast growth factor (bFGF), to thereby maintain the mammalian pluripotent stem cells in an undifferentiated, pluripotent and proliferative state. 2. The method of claim 1, further comprising culturing the mammalian pluripotent stem cells on an extracellular matrix. 3. The method of claim 2, wherein said extracellular matrix is a fibronectin matrix. 4. The method of claim 3, wherein said fibronectin is selected from the group consisting of bovine fibronectin, recombinant bovine fibronectin, human fibronectin, recombinant human fibronectin, mouse fibronectin, recombinant mouse fibronectin, and synthetic fibronectin. 5. The method of claim 2, wherein said culturing conditions are substantially free of animal contaminant and wherein said extracellular matrix is selected from the group consisting of human plasma fibronectin matrix, recombinant human plasma fibronectin matrix, human cellular fibronectin matrix, recombinant human cellular fibronectin matrix, synthetic fibronectin. 6. The method of claim 1, wherein said mammalian pluripotent stem cells are human pluripotent stem cells. 7. The method of claim 1, wherein the mammalian pluripotent stem cells are embryonic stem cells. 8. The method of claim 7, wherein said embryonic stem cells are human embryonic stem cells. 9. The method of claim 1, wherein said tissue culture medium further comprises serum. 10. The method of claim 1, wherein said tissue culture medium further comprises serum replacement. 11. The method of claim 1, wherein said TGFβ1 is provided at a concentration of at least 0.06 ng/ml. 12. The method of claim 1, wherein said bFGF is provided at a concentration of at least 2 ng/ml. 13. The method of claim 1, further comprises leukemia inhibitor factor (LIF). 14. The method of claim 13, wherein said LIF is provided at a concentration of at least 500 u/ml. 15. A cell culture comprising mammalian pluripotent stem cells in a culture medium which comprises transforming growth factor β1 (TGFβ1) and basic fibroblast growth factor (bFGF), wherein the cell culture is substantially free of animal- and/or feeder cells contaminants and whereas said mammalian pluripotent stem cells are maintained in an undifferentiated, pluripotent and proliferative state when cultured in said culture medium. 16. The cell culture of claim 15, wherein the culture medium comprises serum replacement. 17. The cell culture of claim 16, wherein said serum replacement is provided at a concentration of at least 10%. 18. The cell culture of claim 15, wherein said TGFβ1 is provided at a concentration of at least 0.06 ng/ml. 19. The cell culture of claim 15, wherein said bFGF is provided at a concentration of at least 2 ng/ml. 20. The cell culture of claim 15, wherein said culture medium further comprises leukemia inhibitor factor (LIF). 21. The cell culture of claim 20, wherein said LIF is provided at a concentration of at least 500 u/ml. 22. The cell culture of claim 15, wherein said mammalian pluripotent stem cells are maintained in an undifferentiated, pluripotent and proliferative state for at least 38 passages when cultured in said culture medium. 23. The cell culture of claim 15, wherein said mammalian pluripotent stem cells are human embryonic stem cells. 24. A method of propagating cells in a culture, comprising culturing the cells in a culture medium which comprises transforming growth factor β1 (TGFβ1) and basic fibroblast growth factor (bFGF), wherein said bFGF is provided at a concentration of at least 2 ng/ml, and wherein said TGFβ1 is provided at a concentration range of 0.06-0.24 ng/ml, there propagating the cells in the culture. 25. A cell culture comprising cells and a culture medium, wherein said culture medium comprises transforming growth factor β1 (TGFβ1) and basic fibroblast growth factor (bFGF), wherein said bFGF is provided at a concentration of at least 2 ng/ml, and wherein said TGFβ1 is provided at a concentration range of 0.06-0.24 ng/ml.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.